A Novel Gene Underlies Bleomycin-Response Variation in Caenorhabditis elegans

Shannon C. Brady, Stefan Zdraljevic, Karol W. Bisaga, Robyn Elizabeth Tanny, Daniel E. Cook, Daehan Lee, Ye Wang, Erik Christian Andersen

Research output: Contribution to journalArticle

Abstract

Bleomycin is a powerful chemotherapeutic drug used to treat a variety of cancers. However, individual patients vary in their responses to bleomycin. The identification of genetic differences that underlie this response variation could improve treatment outcomes by tailoring bleomycin dosages to each patient. We used the model organism Caenorhabditis elegans to identify genetic determinants of bleomycin-response differences by performing linkage mapping on recombinants derived from a cross between the laboratory strain (N2) and a wild strain (CB4856). This approach identified a small genomic region on chromosome V that underlies bleomycin-response variation. Using near-isogenic lines, and strains with CRISPR-Cas9 mediated deletions and allele replacements, we discovered that a novel nematode-specific gene (scb-1) is required for bleomycin resistance. Although the mechanism by which this gene causes variation in bleomycin responses is unknown, we suggest that a rare variant present in the CB4856 strain might cause differences in the potential stress-response function of scb-1 between the N2 and CB4856 strains, thereby leading to differences in bleomycin resistance.

Original languageEnglish (US)
Pages (from-to)1453-1468
Number of pages16
JournalGenetics
Volume212
Issue number4
DOIs
StatePublished - Aug 1 2019

Fingerprint

Bleomycin
Caenorhabditis elegans
Genes
Clustered Regularly Interspaced Short Palindromic Repeats
Chromosome Mapping
Chromosomes
Alleles
Pharmaceutical Preparations
Neoplasms

Keywords

  • C. elegans bleomycin
  • QTL
  • drug-response
  • linkage mapping

ASJC Scopus subject areas

  • Genetics

Cite this

Brady, Shannon C. ; Zdraljevic, Stefan ; Bisaga, Karol W. ; Tanny, Robyn Elizabeth ; Cook, Daniel E. ; Lee, Daehan ; Wang, Ye ; Andersen, Erik Christian. / A Novel Gene Underlies Bleomycin-Response Variation in Caenorhabditis elegans. In: Genetics. 2019 ; Vol. 212, No. 4. pp. 1453-1468.
@article{5512f70df4a8473d88842251c1326c54,
title = "A Novel Gene Underlies Bleomycin-Response Variation in Caenorhabditis elegans",
abstract = "Bleomycin is a powerful chemotherapeutic drug used to treat a variety of cancers. However, individual patients vary in their responses to bleomycin. The identification of genetic differences that underlie this response variation could improve treatment outcomes by tailoring bleomycin dosages to each patient. We used the model organism Caenorhabditis elegans to identify genetic determinants of bleomycin-response differences by performing linkage mapping on recombinants derived from a cross between the laboratory strain (N2) and a wild strain (CB4856). This approach identified a small genomic region on chromosome V that underlies bleomycin-response variation. Using near-isogenic lines, and strains with CRISPR-Cas9 mediated deletions and allele replacements, we discovered that a novel nematode-specific gene (scb-1) is required for bleomycin resistance. Although the mechanism by which this gene causes variation in bleomycin responses is unknown, we suggest that a rare variant present in the CB4856 strain might cause differences in the potential stress-response function of scb-1 between the N2 and CB4856 strains, thereby leading to differences in bleomycin resistance.",
keywords = "C. elegans bleomycin, QTL, drug-response, linkage mapping",
author = "Brady, {Shannon C.} and Stefan Zdraljevic and Bisaga, {Karol W.} and Tanny, {Robyn Elizabeth} and Cook, {Daniel E.} and Daehan Lee and Ye Wang and Andersen, {Erik Christian}",
year = "2019",
month = "8",
day = "1",
doi = "10.1534/genetics.119.302286",
language = "English (US)",
volume = "212",
pages = "1453--1468",
journal = "Genetics",
issn = "0016-6731",
publisher = "Genetics Society of America",
number = "4",

}

Brady, SC, Zdraljevic, S, Bisaga, KW, Tanny, RE, Cook, DE, Lee, D, Wang, Y & Andersen, EC 2019, 'A Novel Gene Underlies Bleomycin-Response Variation in Caenorhabditis elegans', Genetics, vol. 212, no. 4, pp. 1453-1468. https://doi.org/10.1534/genetics.119.302286

A Novel Gene Underlies Bleomycin-Response Variation in Caenorhabditis elegans. / Brady, Shannon C.; Zdraljevic, Stefan; Bisaga, Karol W.; Tanny, Robyn Elizabeth; Cook, Daniel E.; Lee, Daehan; Wang, Ye; Andersen, Erik Christian.

In: Genetics, Vol. 212, No. 4, 01.08.2019, p. 1453-1468.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A Novel Gene Underlies Bleomycin-Response Variation in Caenorhabditis elegans

AU - Brady, Shannon C.

AU - Zdraljevic, Stefan

AU - Bisaga, Karol W.

AU - Tanny, Robyn Elizabeth

AU - Cook, Daniel E.

AU - Lee, Daehan

AU - Wang, Ye

AU - Andersen, Erik Christian

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Bleomycin is a powerful chemotherapeutic drug used to treat a variety of cancers. However, individual patients vary in their responses to bleomycin. The identification of genetic differences that underlie this response variation could improve treatment outcomes by tailoring bleomycin dosages to each patient. We used the model organism Caenorhabditis elegans to identify genetic determinants of bleomycin-response differences by performing linkage mapping on recombinants derived from a cross between the laboratory strain (N2) and a wild strain (CB4856). This approach identified a small genomic region on chromosome V that underlies bleomycin-response variation. Using near-isogenic lines, and strains with CRISPR-Cas9 mediated deletions and allele replacements, we discovered that a novel nematode-specific gene (scb-1) is required for bleomycin resistance. Although the mechanism by which this gene causes variation in bleomycin responses is unknown, we suggest that a rare variant present in the CB4856 strain might cause differences in the potential stress-response function of scb-1 between the N2 and CB4856 strains, thereby leading to differences in bleomycin resistance.

AB - Bleomycin is a powerful chemotherapeutic drug used to treat a variety of cancers. However, individual patients vary in their responses to bleomycin. The identification of genetic differences that underlie this response variation could improve treatment outcomes by tailoring bleomycin dosages to each patient. We used the model organism Caenorhabditis elegans to identify genetic determinants of bleomycin-response differences by performing linkage mapping on recombinants derived from a cross between the laboratory strain (N2) and a wild strain (CB4856). This approach identified a small genomic region on chromosome V that underlies bleomycin-response variation. Using near-isogenic lines, and strains with CRISPR-Cas9 mediated deletions and allele replacements, we discovered that a novel nematode-specific gene (scb-1) is required for bleomycin resistance. Although the mechanism by which this gene causes variation in bleomycin responses is unknown, we suggest that a rare variant present in the CB4856 strain might cause differences in the potential stress-response function of scb-1 between the N2 and CB4856 strains, thereby leading to differences in bleomycin resistance.

KW - C. elegans bleomycin

KW - QTL

KW - drug-response

KW - linkage mapping

UR - http://www.scopus.com/inward/record.url?scp=85071354481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071354481&partnerID=8YFLogxK

U2 - 10.1534/genetics.119.302286

DO - 10.1534/genetics.119.302286

M3 - Article

VL - 212

SP - 1453

EP - 1468

JO - Genetics

JF - Genetics

SN - 0016-6731

IS - 4

ER -